JP2007506734A5 - - Google Patents

Download PDF

Info

Publication number
JP2007506734A5
JP2007506734A5 JP2006527944A JP2006527944A JP2007506734A5 JP 2007506734 A5 JP2007506734 A5 JP 2007506734A5 JP 2006527944 A JP2006527944 A JP 2006527944A JP 2006527944 A JP2006527944 A JP 2006527944A JP 2007506734 A5 JP2007506734 A5 JP 2007506734A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006527944A
Other languages
Japanese (ja)
Other versions
JP2007506734A (ja
Filing date
Publication date
Priority claimed from SE0302546A external-priority patent/SE0302546D0/xx
Application filed filed Critical
Publication of JP2007506734A publication Critical patent/JP2007506734A/ja
Publication of JP2007506734A5 publication Critical patent/JP2007506734A5/ja
Pending legal-status Critical Current

Links

JP2006527944A 2003-09-24 2004-09-21 新規な化合物 Pending JP2007506734A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302546A SE0302546D0 (sv) 2003-09-24 2003-09-24 New compounds
PCT/SE2004/001363 WO2005027823A2 (en) 2003-09-24 2004-09-21 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)

Publications (2)

Publication Number Publication Date
JP2007506734A JP2007506734A (ja) 2007-03-22
JP2007506734A5 true JP2007506734A5 (enExample) 2007-11-08

Family

ID=29212538

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006527944A Pending JP2007506734A (ja) 2003-09-24 2004-09-21 新規な化合物

Country Status (13)

Country Link
US (1) US7683067B2 (enExample)
EP (1) EP1667990A2 (enExample)
JP (1) JP2007506734A (enExample)
CN (1) CN1886397A (enExample)
AR (1) AR045793A1 (enExample)
AU (1) AU2004273771B2 (enExample)
BR (1) BRPI0414632A (enExample)
CA (1) CA2538381A1 (enExample)
MX (1) MXPA06003195A (enExample)
SE (1) SE0302546D0 (enExample)
TW (1) TW200526627A (enExample)
UY (1) UY28528A1 (enExample)
WO (1) WO2005027823A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
JP2009525325A (ja) * 2006-02-02 2009-07-09 アストラゼネカ・アクチエボラーグ 2−ヒドロキシ−3−[5−(モルホリン−4−イルメチル)ピリジン−2−イル]1h−インドール−5−カルボニトリルの遊離塩基又は塩としての医薬用途
JP2009528344A (ja) * 2006-02-28 2009-08-06 アストラゼネカ・アクチエボラーグ インドール誘導体の新規な塩及び医薬におけるその使用
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007120102A1 (en) * 2006-04-19 2007-10-25 Astrazeneca Ab New substituted oxindole derivatives
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20090291982A1 (en) * 2008-05-22 2009-11-26 Astrazeneca Ab New Substituted Oxindole Derivative 352
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TW201040191A (en) * 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2377850A1 (en) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2655361B1 (de) 2010-12-21 2016-02-24 Bayer Intellectual Property GmbH Verfahren zur herstellung von triazinylsubstituierten oxindolen
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
WO2021243040A2 (en) * 2020-05-29 2021-12-02 The Regents Of The University Of Michigan Small molecule inhibitors of grk5 and grk5 subfamily members and uses thereof
CN119118901B (zh) * 2024-09-09 2025-09-30 中国人民解放军北部战区总医院 一种氧吲哚类衍生物及其制备方法与在trpa1抑制剂方向的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5940149B2 (ja) * 1977-11-09 1984-09-28 大塚製薬株式会社 オキシインド−ル誘導体
US5565580A (en) 1994-01-27 1996-10-15 Neurosearch A/S Glutamate Antagonists
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US6569868B2 (en) * 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CZ303660B6 (cs) 1999-05-21 2013-02-13 Bristol-Myers Squibb Company Pyrrolotriazin a farmaceutický prostredek s jeho obsahem
JP2003511378A (ja) 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
IL153851A0 (en) 2000-07-27 2003-07-31 Hoffmann La Roche 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
HUP0303559A3 (en) * 2000-10-13 2006-02-28 Bristol Myers Squibb Co Selective maxi-k-potassium channel openers functional under conditions of high intracellular calcium concentration and uses thereof
SE0104341D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New use
SE0104340D0 (sv) * 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
AU2002359162A1 (en) 2001-12-21 2003-07-15 Astrazeneca Ab Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
RU2004135382A (ru) 2002-06-05 2005-06-27 Янссен Фармацевтика Н.В. (Be) Замещенные пирролины в качестве ингибиторов киназы

Similar Documents

Publication Publication Date Title
IN2014DN10699A (enExample)
JP2005041774A5 (enExample)
JP2005145434A5 (enExample)
JP2005009494A5 (enExample)
JP2004347112A5 (enExample)
JP2004251909A5 (enExample)
IN2006DE07971A (enExample)
JP2005196678A5 (enExample)
JP2005064470A5 (enExample)
JP2005233287A5 (enExample)
JP2005197975A5 (enExample)
JP2005032703A5 (enExample)
JP2005011489A5 (enExample)
JP2005202044A5 (enExample)
JP2004228094A5 (enExample)
JP2005244727A5 (enExample)
JP2005238894A5 (enExample)
JP2005224034A5 (enExample)
JP2005014208A5 (enExample)
JP2005282110A5 (enExample)
JP2005226869A5 (enExample)
JP2005087723A5 (enExample)
JP2005266609A5 (enExample)
CN300732651S (zh) 起动器的主体
CN300741012S (zh)